Skyviews Life Science
Antoine TELLE has extensive experience in the field of finance and operations. Antoine currently holds the position of Operations and Business Development Director at Skyviews Life Science since October 2021. Prior to that, they worked at Alantra as an M&A Vice President from January 2018 to July 2020 and as an M&A Associate from January 2016 to December 2017. Antoine also served as an M&A Associate and Analyst at C.W. Downer & Co. from July 2014 to May 2016 and from September 2012 to June 2014, respectively. Antoine TELLE began their career at CMW Corporate Finance as a Senior Analyst (M&A) from August 2010 to September 2012. Antoine also gained valuable experience as an International Junior Consultant and M&A Analyst at Euro-Phoenix from September 2009 to June 2010 and from April 2009 to September 2009, respectively. Antoine started their professional journey as a Summer Intern at International SOS in 2005 and later served as an International Operations Coordinator from July 2008 to January 2009.
Antoine TELLE pursued their education chronologically as follows:
From 1998 to 2004, they attended St Dominique, where they did not obtain a degree or specify a field of study.
Antoine then joined Classes Préparatoires Notre Dame de Sainte-Croix during the period of 2004 to 2006, again without obtaining a degree or specifying a field of study.
From 2006 to 2010, they studied at SKEMA Business School, completing a Master's degree in International Masters in Management.
In 2009 to 2010, they also pursued a Master's degree in International Financial Analysis at Ecole Supérieure des Affaires.
This person is not in any teams
This person is not in any offices
Skyviews Life Science
Skyviews Life Science is a privately held advisory company specialised in personalised health. They are designed to identify investment opportunities in companies at the growing interface between biotechnology, advanced nutrition and digital health. Thye target private and public companies with better drugs, advanced technology platforms, preventive strategies, personalized solutions and more natural foods that will improve people’s quality of life. They are a team of experienced professionals from the academic, corporate, consumer and venture capital sectors. They leverage worldwide networks and work closely with partner organizations to identify outstanding value for their clients, for patients, for healthcare payors and for capital. Their perspective is rooted in “P4 medicine”, evolving from reactive disease care to care that is predictive, preventive, personalized and participatory. This new paradigm focuses on big data, better lifestyles and tailored treatments, building on the evidence that each individual’s health experience is unique.